PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22962305-0	2012	Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B.	Ceftriaxone	0-11	aurora kinase B	Homo sapiens	98-106	
22962305-6	2012	Kinase profiling results predicted that Aurora B might be a potential "off" target of ceftriaxone.	Ceftriaxone	86-97	aurora kinase B	Homo sapiens	40-48	
22962305-7	2012	Pull-down assay data confirmed that ceftriaxone could bind with Aurora B in vitro and in A549 cells.	Ceftriaxone	36-47	aurora kinase B	Homo sapiens	64-72	
22962305-8	2012	Furthermore, ceftriaxone (500 microM) suppressed anchorage-independent cell growth by targeting Aurora B in A549, H520 and H1650 lung cancer cells.	Ceftriaxone	13-24	aurora kinase B	Homo sapiens	96-104	
22962305-9	2012	Importantly, in vivo xenograft animal model results showed that ceftriaxone effectively suppressed A549 and H520 lung tumor growth by inhibiting Aurora B.	Ceftriaxone	64-75	aurora kinase B	Homo sapiens	145-153	
22962305-10	2012	These data suggest the anticancer efficacy of ceftriaxone for the treatment of lung cancers through its inhibition of Aurora B.	Ceftriaxone	46-57	aurora kinase B	Homo sapiens	118-126